Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Revlimid (lenalidomide)-Important Safety Information from Celgene as approved by the Irish Medicines Board 08.07.2008
Notice type:
3rd Party Publications
Date:
08/07/2008
Problem Or Issue:
Please find herewith an important safety communication from Celgene Limited regarding new preclinical safety information on teratogenicity from ongoing primate embryofoetal development study relating to Revlimid (lenalidomide)
« Back
Date Printed: 18/05/2024